Key points from article :
Genflow announced a scientific research collaboration with the University of Rochester’s Aging Research Center (RoAR).
Collaboration will initially research the potential of Sirtuin-6 (SIRT6) in reversing the aging process in liver tissue.
According to Genflow, “The first step towards a true rejuvenation gene therapy across a range of tissues.”
SIRT6 gene mutation’s potential to not just halt the aging process, but to reverse it.
Adeno-associated virus vectors to deliver copies of the SIRT6 gene variant directly into cells.
Initially, to explore the ability of gene therapy for the rejuvenation of the liver.
Data will support the pre-clinical trials and development of gene therapies.
Genflow is confident this collaboration will provide it with a deeper presence in, and exposure to, the US.
Eric Leire, Founder and CEO of Genflow, said: “A novel gene therapy for not only improving healthy aging, but also offering the opportunity of epigenetic tissue rejuvenation.”
